{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:19Z","timestamp":1793745319474,"version":"4.6.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular disease, and it is particularly associated with premature acute coronary syndrome (ACS). We investigated whether elevated Lp(a) can predict recurrent cardiovascular events in patients who experienced their first ACS less than or equal to 40 years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Within the STudy of eArly Myocardial INfArction registry, we recruited 405 consecutive patients who survived their first ACS less than or equal to 40 years of age; of them 378 had complete follow-up data. Clinical endpoint was the development of major adverse cardiovascular events (MACE; i.e. cardiac death, readmission for ACS or malignant ventricular arrhythmias, ischemic stroke, or coronary revascularization due to clinical deterioration). Multi-adjusted Cox regression was used to assess the association between Lp(a) and first recurrent MACE risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 378 ACS survivors (33.7\u2005\u00b1\u20054.3 years), 139 (36.8%) experienced a MACE over a median 8-year (5.2\u201312.5 years) follow-up. Elevated Lp(a) showed a borderline independent association with higher recurrent MACE [hazard ratio per 1\u2005mg\/dl: 1.004, 95% confidence interval (CI): 0.999\u20131.009,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.051]. Moreover, patients with baseline Lp(a) levels greater than or equal to 50\u2005mg\/dl had 82.6% higher risk of MACE as compared with those below (hazard ratio 1.826, 95% CI: 1.141\u20132.925,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.012); similarly, patients with Lp(a)\u2005\u2265\u200570\u2005mg\/dl had 118% higher risk as compared with those below (hazard ratio 2.180, 95% CI: 1.330\u20133.573,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated Lp(a) concentrations demonstrate an independent association with recurrent MACE among very young ACS survivors. Until targeted Lp(a)-lowering treatments become clinically available, an aggressive lipid-lowering approach may be warranted to partially attenuate Lp(a)-related residual cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mca.0000000000001627","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:00:50Z","timestamp":1773043250000},"page":"432-438","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Lipoprotein(a) as a predictor of major adverse cardiovascular events in patients with very premature (\u226440 years) acute coronary syndrome: long-term follow-up of the STudy of eArly Myocardial INfArction"],"prefix":"10.1097","volume":"37","author":[{"given":"Loukianos S.","family":"Rallidis","sequence":"first","affiliation":[{"name":"Second Department of Cardiology, Medical School, National and Kapodistrian University of Athens, University General Hospital ATTIKON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia-Panagiota","family":"Giannakopoulou","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Kotakos","sequence":"additional","affiliation":[{"name":"Cardiology Department, 251 Hellenic Air Force General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Armylagos","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Medical School, National and Kapodistrian University of Athens, University General Hospital ATTIKON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos L.","family":"Rallidis","sequence":"additional","affiliation":[{"name":"Biomedical Sciences, Medical School, University of Nicosia, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni P.","family":"Stathopoulou","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Unit, University General Hospital ATTIKON, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos A.","family":"Papathanasiou","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Medical School, National and Kapodistrian University of Athens, University General Hospital ATTIKON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demosthenes","family":"Panagiotakos","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"R1-20260731","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.jacc.2022.04.015","article-title":"Causes, angiographic characteristics, and management of premature myocardial infarction: JACC state-of-the-art review.","volume":"79","author":"Rallidis","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R2-20260731","doi-asserted-by":"crossref","first-page":"e008112","DOI":"10.1161\/CIRCOUTCOMES.121.008112","article-title":"Ten-year trends in patient characteristics, treatments, and outcomes in myocardial infarction from national cardiovascular data registry chest pain-mi registry.","volume":"15","author":"Gandhi","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R3-20260731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2018.10.017","article-title":"Early onset ACS: An age based clinico-epidemiologic and angiographic comparison.","volume":"279","author":"Chhabra","year":"2018","journal-title":"Atherosclerosis"},{"key":"R4-20260731","doi-asserted-by":"crossref","first-page":"e017712","DOI":"10.1161\/JAHA.120.017712","article-title":"Risk factor burden and long-term prognosis of patients with premature coronary artery disease.","volume":"9","author":"Zeitouni","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R5-20260731","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association.","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R6-20260731","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacl.2022.08.007","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association.","volume":"16","author":"Wilson","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R7-20260731","doi-asserted-by":"crossref","first-page":"103843","DOI":"10.1016\/j.numecd.2024.103843","article-title":"Role of LipoprotEin(a) in cardiovascular diseases and premature acute coronary syndromes (RELACS study): impact of lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease.","volume":"35","author":"Cesaro","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R8-20260731","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MCA.0000000000001233","article-title":"Lipoprotein(a) is associated with premature coronary artery disease: a meta-analysis.","volume":"34","author":"Papathanasiou","year":"2023","journal-title":"Coron Artery Dis"},{"key":"R9-20260731","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2017.12.011","article-title":"High levels of lipoprotein (a) and premature acute coronary syndrome.","volume":"269","author":"Rallidis","year":"2018","journal-title":"Atherosclerosis"},{"key":"R10-20260731","doi-asserted-by":"crossref","first-page":"oeae031","DOI":"10.1093\/ehjopen\/oeae031","article-title":"Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis.","volume":"4","author":"Tian","year":"2024","journal-title":"Eur Heart J Open"},{"key":"R11-20260731","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects.","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"R12-20260731","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease.","volume":"63","author":"O\u2019Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R13-20260731","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jacl.2018.08.012","article-title":"Lipoprotein(a) and secondary prevention of atherothrombotic events: a critical appraisal.","volume":"12","author":"Boffa","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R14-20260731","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.78.2.131","article-title":"Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery.","volume":"78","author":"Skinner","year":"1997","journal-title":"Heart"},{"key":"R15-20260731","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.amjcard.2017.06.002","article-title":"Characteristics and long-term prognosis of patients \u226435 years of age with ST segment elevation myocardial infarction and \u2018normal or near normal\u2019 coronary arteries.","volume":"120","author":"Rallidis","year":"2017","journal-title":"Am J Cardiol"},{"key":"R16-20260731","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejim.2015.05.014","article-title":"Circadian pattern of symptoms onset in patients \u226435 years presenting with ST-segment elevation acute myocardial infarction.","volume":"26","author":"Rallidis","year":"2015","journal-title":"Eur J Intern Med"},{"key":"R17-20260731","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/00033197241232567","article-title":"Gender differences among very young patients with acute coronary syndrome: long-term follow-up of the STAMINA study.","volume":"76","author":"Papathanasiou","year":"2024","journal-title":"Angiology"},{"key":"R18-20260731","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"R19-20260731","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R20-20260731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a).","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"R21-20260731","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests.","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"R22-20260731","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2307\/2532206","article-title":"Maximum likelihood estimation of the attributable fraction from logistic models.","volume":"49","author":"Greenland","year":"1993","journal-title":"Biometrics"},{"key":"R23-20260731","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/1536867X1301300402","article-title":"Attributable and unattributable risks and fractions and other scenario comparisons.","volume":"13","author":"Newson","year":"2013","journal-title":"Stata J"},{"key":"R24-20260731","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality.","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"R25-20260731","doi-asserted-by":"crossref","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels International Declaration on Lipoprotein(a) testing and management.","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"key":"R26-20260731","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention.","volume":"14","author":"Yoon","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R27-20260731","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"R28-20260731","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias.","volume":"406","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"R29-20260731","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/ATVBAHA.124.319483","article-title":"Lipoprotein(a) in the year 2024: a look back and a look ahead.","volume":"44","author":"Tsimikas","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R30-20260731","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database.","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"R31-20260731","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"R32-20260731","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.jacl.2024.07.001","article-title":"Addressing residual risk beyond statin therapy: new targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.","volume":"18","author":"Mach","year":"2024","journal-title":"J Clin Lipidol"},{"key":"R33-20260731","doi-asserted-by":"crossref","first-page":"117437","DOI":"10.1016\/j.atherosclerosis.2023.117437","article-title":"Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK Biobank.","volume":"389","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"key":"R34-20260731","doi-asserted-by":"crossref","first-page":"105499","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the international lipid expert panel (ILEP).","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:01:13Z","timestamp":1785484873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001627","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-09-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}